Assessment of C-X-C Motif Chemokine Ligand 10 (CXCL10) Serum Level in Patients with Vitiligo | ||
| Suez Canal University Medical Journal | ||
| Article 11, Volume 26, Issue 2, February 2023, Pages 0-0 | ||
| Document Type: Original Article | ||
| DOI: 10.21608/scumj.2023.304782 | ||
| Authors | ||
| Sahar Sleem* 1; Radwa Marie2; Noha Kamel3; Mona Atwa2 | ||
| 1Department of Dermatology, Ministry of Health and Population, Faqous General Hospital, El Sharqia, Egypt | ||
| 2Department of Dermatology, Venereology and Andrology, Faculty of Medicine, Suez Canal University, Egypt. | ||
| 3Department of Clinical Pathology, Faculty of Medicine, Suez Canal University, Egypt | ||
| Abstract | ||
| Background: Vitiligo is a common depigmentation disorder that affects 0.1% to 2% of the population. Patients with vitiligo have an increase in autoreactive CD8+ T cells that target melanocytes in their serum and skin, resulting in melanocyte cytotoxicity.CXCL10 chemokine binds the CXCR3 receptor expressed on T cells, monocytes, and natural killer cells inducing their tissue recruitment.CXCL10 plays a role in many autoimmune diseases. Aim: Evaluate CXCL10 serum level in patients with vitiligocompared to healthy controls and detect its correlation with the disease activity.Methods:In this case-control study, 20 vitiligo patients and 20 healthy controls were enrolled. An enzyme-linked immunosorbent assay was used to compare the serum level of CXCL10 in vitiligo patients to healthy controls (ELISA).Results: The level of CXCL10serum was noticeably higher in patients with vitiligo than in controls (p=0.021) and correlated positively with disease activity (VIDA) (p < 0.001).Conclusion:CXCL10 might have a role in the pathogenesis of vitiligo and might serve as a marker for disease activity.Further large-scale studies are needed to confirm the definite role of CXCL10 in vitiligo pathogenesis. | ||
| Keywords | ||
| Vitiligo; Autoimmunity; CXCL10 | ||
|
Statistics Article View: 219 |
||
